[{"question_number":"11","question":"What electroencephalogram (EEG) finding suggests a poor prognosis?","options":["Prolonged suppression","Prolonged burst","High amplitude burst","Variation of burst suppression ## Page 27"],"correct_answer":"A","correct_answer_text":"Prolonged suppression","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is correct: prolonged suppression intervals (>10 seconds) on a burst\u2010suppression EEG pattern in neonates correlate strongly with poor neurological outcome and mortality. Option B (prolonged burst) actually suggests periods of preserved cortical activity. Option C (high\u2010amplitude burst) indicates relatively intact excitatory networks and may carry a better prognosis. Option D (variation in burst\u2010suppression) reflects heterogeneity and intermittency, which can be associated with some recovery.","conceptual_foundation":"Burst suppression in neonatal EEG is categorized by alternating high\u2010voltage bursts and isoelectric suppression phases. Prolonged suppression is a marker of severe global cortical dysfunction, often due to hypoxic\u2010ischemic encephalopathy or massive metabolic insult. Classification systems for neonatal encephalopathy integrate EEG patterns into prognostic scoring. Differential includes sedation effects and deep coma.","pathophysiology":"Neuronal networks under severe insult show failure of synaptic transmission, leading to periods of electrical silence. Prolonged suppression indicates a threshold of injury beyond which intrinsic excitability cannot be maintained. This is due to energy failure, ionic pump dysfunction, and widespread neuronal apoptosis.","clinical_manifestation":"Clinically, neonates with prolonged suppression lack spontaneous movements, have absent brainstem reflexes, and show poor autonomic regulation. Seizures may be minimal or absent. These findings correlate with a high risk of death or severe neurodevelopmental impairment in survivors.","diagnostic_approach":"Continuous EEG monitoring in critically ill neonates identifies burst suppression. Quantitative EEG metrics can measure suppression duration. MRI and ultrasound may reveal underlying hypoxic\u2010ischemic injury. Suppression durations >10 seconds on multiple occasions predict poor outcome.","management_principles":"Management focuses on supportive care, targeted temperature management for HIE, and avoidance of sedatives that might deepen suppression. Seizure control with antiepileptic drugs is secondary, as seizure burden often is low. Ethical considerations regarding withdrawal of care arise when prolonged suppression persists despite interventions.","follow_up_guidelines":"If spontaneous improvement of EEG pattern occurs within 48\u201372 hours, prognosis may improve; otherwise, ongoing supportive care and family counseling guide decisions. Neurodevelopmental follow\u2010up assesses motor, cognitive, and sensory outcomes. Early palliative care involvement may be necessary.","clinical_pearls":"1. Suppression intervals >10 seconds are the single most reliable EEG predictor of poor outcome in neonatal encephalopathy. 2. Sedative medications can confound EEG interpretation\u2014correlate clinically. 3. High\u2010amplitude bursts suggest residual cortical function. 4. Continuous EEG is superior to intermittent recordings for prognosis. 5. Ethical discussions should incorporate EEG prognostic data within 72 hours.","references":"1. Murray DM, Boylan GB, Ali I, et al. Defining the gap between electroencephalographic and clinicopathologic features of neonatal hypoxic\u2010ischemic encephalopathy. Pediatrics. 2009;124(3):e459\u2013e467. 2. Hellstr\u00f6m\u2010Westas L, Ros\u00e9n I. Amplitude\u2010integrated EEG in neonatal seizure detection. Arch Dis Child Fetal Neonatal Ed. 2011;96(2):F102\u2013F106. 3. Thiagarajan R, Fink EL. Continuous EEG monitoring in pediatric critical care. J Clin Neurophysiol. 2014;31(4):328\u2013336."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"1","question":"An infant presents with a head circumference at the 100th percentile, height at the 10th percentile, and weight at the 20th percentile. The infant also has multiple caf\u00e9 au lait spots and axillary flickering. What is the most likely diagnosis?","options":["Neurofibromatosis Type 1 (NF1)","Neurofibromatosis Type 2 (NF2)","Tuberous Sclerosis Complex (TSC)","Fetal Alcohol Spectrum Disorder ## Page 18"],"correct_answer":"A","correct_answer_text":"Neurofibromatosis Type 1 (NF1)","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is most accurate. NF1 presents in infancy or early childhood with macrocephaly (head circumference often >97th percentile), caf\u00e9 au lait spots, and axillary freckling due to mutation in the NF1 tumor suppressor gene. Option B (NF2) is characterized by bilateral vestibular schwannomas and meningiomas without cutaneous caf\u00e9 au lait macules or axillary freckling. Option C (TSC) features hypopigmented ash leaf spots, facial angiofibromas, cortical tubers, seizures, and cardiac rhabdomyomas rather than caf\u00e9 au lait spots. Option D (Fetal Alcohol Spectrum Disorder) causes growth restriction, facial dysmorphism, neurodevelopmental delay, and microcephaly rather than macrocephaly and caf\u00e9 au lait spots.","conceptual_foundation":"NF1 is an autosomal dominant neurocutaneous syndrome with complete penetrance and variable expression, ICD-11 Q85.01. First described by von Recklinghausen in 1882, it arises from a germline mutation in the NF1 gene on chromosome 17q11.2 which encodes neurofibromin, a GTPase activating protein regulating RAS. Embryologically, neural crest derived Schwann cells and melanocytes give rise to neurofibromas and caf\u00e9 au lait macules. Differential diagnoses include Legius syndrome (SPRED1 mutation) which causes caf\u00e9 au lait spots without neurofibromas, and NF2 which lacks cutaneous stigmata. Family history is positive in ~50% of cases and de novo mutations account for the remainder.","pathophysiology":"Neurofibromin negatively regulates the RAS/MAPK pathway by accelerating conversion of active RAS-GTP to inactive RAS-GDP. Loss of function NF1 mutations lead to constitutive RAS activation, Schwann cell proliferation, and formation of neurofibromas. Hyperproliferation of melanocytes produces caf\u00e9 au lait macules and axillary freckling. Genetic second hits in Schwann cells can result in plexiform neurofibromas and optic pathway gliomas. Macrocephaly may reflect generalized somatic overgrowth and accumulation of tumor mass. The same pathway dysregulation underlies increased risk of malignant peripheral nerve sheath tumors (MPNSTs).","clinical_manifestation":"Diagnostic NIH criteria require two or more of: six or more caf\u00e9 au lait spots \u22655 mm prepubertal or \u226515 mm postpubertal, two or more neurofibromas or one plexiform neurofibroma, axillary/inguinal freckling, optic glioma, two or more Lisch nodules, distinctive osseous lesions, or first-degree relative with NF1. Children typically manifest caf\u00e9 au lait spots in infancy, axillary freckling by 4\u20135 years, and Lisch nodules by school age. Head circumference is frequently \u226597th percentile. Learning disabilities occur in 30\u201365%. Plexiform neurofibromas in 30%, optic pathway gliomas in 15%.","diagnostic_approach":"Clinical diagnosis per NIH consensus (1997). Genetic testing confirms in ambiguous cases. Baseline ophthalmologic exam by age 3, annual exams until age 8, then as indicated. MRI brain/spine if symptomatic. Blood pressure monitoring at each visit to screen for renal artery stenosis or pheochromocytoma. Developmental assessment at regular intervals. Pretest probability in familial cases >90%; genetic testing yield ~95% for point mutations and small deletions.","management_principles":"Multidisciplinary care including neurology, dermatology, oncology, orthopedics, and genetics. Symptomatic neurofibromas managed with surgical excision; MEK inhibitors (selumetinib) show 68% partial response rate in children with inoperable plexiform neurofibromas (Phase II SPRINT trial, 2020). Optic gliomas monitored or treated with carboplatin/vincristine. Hypertension managed per AAP guidelines. Early IEPs for learning disabilities. Genetic counseling for families.","follow_up_guidelines":"Annual physical exam, blood pressure measurement, developmental screening, and school performance monitoring. Annual or biannual ophthalmology visits until age 8, then as clinically indicated. MRI only if new neurologic signs. Monitor for growth of plexiform neurofibromas and signs of malignancy. Lifelong surveillance recommended.","clinical_pearls":"1. Six or more caf\u00e9 au lait spots >5 mm in children or >15 mm in adults is a key NIH criterion; 2. Axillary or inguinal freckling by age 4\u20135 is pathognomonic; 3. Plexiform neurofibromas may undergo malignant transformation\u2014MRI surveillance if symptomatic; 4. Selumetinib (MEK inhibitor) approved for inoperable plexiform neurofibromas in children; 5. Lisch nodules are asymptomatic iris hamartomas best seen on slit lamp exam.","references":"1. Williams VC et al. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123(1):124-133. DOI:10.1542/peds.2008-0311 2. Ferner RE et al. Guidelines for the diagnosis and management of NF1. J Med Genet. 2007;44(2):81-88. DOI:10.1136/jmg.2006.045906 3. Gross AM et al. Selumetinib in children with NF1-related plexiform neurofibromas. N Engl J Med. 2020;382(15):1430-1442. DOI:10.1056/NEJMoa1912735 4. Rosser TL et al. Learning disabilities in NF1: Pathogenesis and management. Curr Neurol Neurosci Rep. 2019;19(12):100. DOI:10.1007/s11910-019-1011-6"},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"1","question":"A child with a facial port wine stain and a computed tomography (CT) brain showing tram-track calcification is diagnosed with:","options":["Sturge-Weber syndrome","Neurofibromatosis","Tuberous sclerosis","Meningioma"],"correct_answer":"A","correct_answer_text":"Sturge-Weber syndrome","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is correct. Sturge\u2013Weber syndrome is a congenital neurocutaneous disorder characterized by a facial port wine stain in the distribution of the trigeminal nerve and ipsilateral leptomeningeal angiomas causing gyriform (\u2018tram-track\u2019) calcifications on CT. Option B (Neurofibromatosis) presents with caf\u00e9 au lait spots and neurofibromas, not port wine stains or leptomeningeal angiomas. Option C (Tuberous sclerosis) features hypopigmented \u2018ash leaf\u2019 spots and cortical tubers with subependymal nodules, not port wine stain or tram-track calcifications. Option D (Meningioma) is a neoplasm typically of adults, without cutaneous vascular malformations.","conceptual_foundation":"Sturge\u2013Weber syndrome (encephalotrigeminal angiomatosis) is classified under ICD-11 Q25.3. It is caused by a somatic mosaic mutation in GNAQ leading to vascular malformations of the leptomeninges, skin, and choroid. It is sporadic with no inheritance pattern. Facial port wine stain follows embryonic vascular distributions of the trigeminal nerve. Differential diagnoses include Klippel\u2013Trenaunay syndrome (port wine stain with limb hypertrophy) and PHACE syndrome.","pathophysiology":"Postzygotic activating mutations in GNAQ result in capillary-venous malformations in the skin and leptomeninges. Leptomeningeal angiomas impair venous drainage causing chronic ischemia, cortical atrophy, calcification, and seizure foci. Impaired venous outflow leads to gyral calcifications, seen as tram-track lines. Choroidal angiomas predispose to glaucoma. Vascular proliferation is limited to affected dermatomes and leptomeninges.","clinical_manifestation":"Port wine stain present at birth in ~75% of cases over V1 distribution. Seizures begin in 75\u201390% by age 2 due to underlying leptomeningeal angioma. Hemiparesis, developmental delay, and stroke-like episodes occur. Glaucoma in 30\u201370% of patients. Tram-track calcifications appear on CT after age 1. Neurologic deficits are contralateral to port wine stain.","diagnostic_approach":"Clinical diagnosis supported by neuroimaging. MRI with contrast demonstrates leptomeningeal enhancement; CT shows gyral calcifications. EEG often shows unilateral spikes. Ophthalmologic evaluation for glaucoma. Genetic testing is not routinely performed. Pretest probability is high in presence of facial nevus flammeus and seizures.","management_principles":"Seizure control with antiepileptic drugs (vigabatrin or levetiracetam). Low-dose aspirin (3\u20135 mg/kg/day) may reduce stroke-like episodes by inhibiting platelet aggregation. Pulsed-dye laser therapy is first-line for port wine stain. Glaucoma managed with topical agents or surgery. Hemispherectomy considered for refractory epilepsy with hemiparesis.","follow_up_guidelines":"Annual neurologic assessments for seizure control, developmental screening, and hemiparesis evaluation. MRI only if clinical changes. Annual ophthalmology for glaucoma screening. Dermatology follow-up for laser therapy sessions.","clinical_pearls":"1. Port wine stain in V1 distribution increases risk of leptomeningeal involvement. 2. Tram-track calcifications on CT are pathognomonic. 3. Aspirin prophylaxis may reduce ischemic complications. 4. Early laser therapy yields best cosmetic outcomes. 5. Hemispherectomy can be curative for intractable seizures.","references":"1. Comi AM. Advances in Sturge-Weber syndrome. Pediatr Neurol. 2015;53(6):379-383. DOI:10.1016/j.pediatrneurol.2015.07.008 2. Shirley MD et al. Sturge-Weber clinical spectrum and GNAQ mutations. Nat Genet. 2013;45(9):1042-1046. DOI:10.1038/ng.271 3. Sreenivasalu L et al. Management of seizures in Sturge-Weber syndrome. Epilepsia. 2017;58(4):552-560. DOI:10.1111/epi.13697"},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"2","question":"In a scenario of a young child with seizures, hypotonia, and a cherry red spot, which enzyme is affected?","options":["Hexosaminidase A.","Glucocerebrosidase.","Sphingolipidosis. ## Page 17."],"correct_answer":"A","correct_answer_text":"Hexosaminidase A.","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is correct: Tay\u2013Sachs disease is caused by deficiency of \u03b2-hexosaminidase A, leading to GM2 ganglioside accumulation, cherry-red macula, hypotonia, and seizures in infancy. Option B (glucocerebrosidase) causes Gaucher disease, which presents with hepatosplenomegaly and bone crises without cherry-red spots. Option C is not an enzyme but a class of disorders.","conceptual_foundation":"Tay\u2013Sachs disease is an autosomal recessive GM2 gangliosidosis (ICD-11: 8E61.0). It presents in infancy with neurodegeneration, hypotonia, seizures, and the pathognomonic cherry-red spot due to retinal ganglion cell swelling. Differential includes Niemann\u2013Pick and Sandhoff diseases but those have hepatosplenomegaly or Sandhoff lacks HEX B A-specificity.","pathophysiology":"In normal physiology, hexosaminidase A (\u03b1\u03b2 heterodimer) degrades GM2 ganglioside in lysosomes. HEXA gene mutations abolish enzyme activity, GM2 accumulates in neurons, causing progressive neuronal loss, demyelination, and gliosis. The cherry-red spot arises from pale perifoveal ganglion cell storage contrasting the fovea, which is cell-poor.","clinical_manifestation":"Classic infantile onset features appear at 3\u20136 months: developmental regression, hypotonia, exaggerated startle response, seizures, and blindness. Cherry-red macula seen on fundoscopic exam by 6 months. Death typically by age 4. Juvenile/adult Tay\u2013Sachs variants have later onset and milder course.","diagnostic_approach":"Diagnosis via demonstration of low hexosaminidase A activity in leukocytes or fibroblasts (nearly absent in classic infantile). Genetic testing confirms HEXA mutations. Prenatal diagnosis possible by enzyme assay or molecular testing in chorionic villus sampling/amniocentesis.","management_principles":"No cure exists; management is supportive: seizure control, nutritional support, and physical therapy. Experimental approaches include gene therapy and substrate reduction which remain investigational. Genetic counseling and carrier screening are essential for families.","follow_up_guidelines":"Regular neurologic assessments, seizure management review, nutritional and respiratory support planning. Palliative care involvement is important by 1 year of age. Family psychosocial support and coordination with genetics clinic for recurrence risk counseling.","clinical_pearls":"1. Cherry-red spot plus hypotonia and seizures in an infant = Tay\u2013Sachs until proven otherwise. 2. Absence of hepatosplenomegaly differentiates Tay\u2013Sachs from Niemann\u2013Pick. 3. Carrier screening in at-risk populations (e.g., Ashkenazi Jews) reduces incidence. 4. HEXA activity assay is diagnostic gold standard. 5. No effective disease-modifying therapy\u2014focus on supportive and palliative care.","references":["Myer DL, Wenger DA. Tay\u2013Sachs disease: Clinical features and molecular basis. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill; 2014:3821\u20133865.","Willner JP, Ryder JW, et al. GM2 gangliosidosis: Pathogenesis and current therapeutic approaches. J Neurosci Res. 2016;94(8):627\u2013642. doi:10.1002/jnr.23718","Kaback MM, Desnick RJ. Hexosaminidase A deficiency: Tay\u2013Sachs disease. In: Valle D, et al., eds. The Online Metabolic and Molecular Bases of Inherited Disease. 2019."]},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"1","question":"A young boy presents with cognitive decline and behavioral changes, and has very long-chain fatty acids (VLCFA) in his blood. What is the most likely diagnosis?","options":["X-linked adrenoleukodystrophy","Adrenomyeloneuropathy","Refsum disease","Krabbe disease"],"correct_answer":"A","correct_answer_text":"X-linked adrenoleukodystrophy","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A: X-linked adrenoleukodystrophy (X-ALD) presents in boys aged 4\u201310 with progressive cognitive decline, behavioral changes, adrenal insufficiency, and elevation of very long-chain fatty acids (VLCFA) in plasma. MRI typically shows symmetric parieto-occipital white matter demyelination. It is confirmed by ABCD1 gene mutation in 95% of cases, making it definitively correct. Option B: Adrenomyeloneuropathy often manifests in adults with spastic paraparesis, peripheral neuropathy, and adrenal dysfunction but lacks the dramatic childhood cognitive decline and classic MRI pattern; VLCFA are elevated in 80% but neurological onset is typically after age 20. Option C: Refsum disease features retinitis pigmentosa, peripheral neuropathy, cerebellar ataxia, and elevated phytanic acid, not VLCFA. Adult onset around 15\u201330 years and skin changes are absent in childhood X-ALD. Option D: Krabbe disease causes galactocerebrosidase deficiency, irritability, seizures, spasticity, optic atrophy, and elevated psychosine, not VLCFA. Onset is usually before six months. Misconceptions arise when any leukodystrophy with adrenal signs is assumed; however, only X-ALD shows ABCD1 mutation with VLCFA >1.0 \u00b5g/mL in plasma in 97% of patients (Moser et al. 2020).","conceptual_foundation":"X-linked adrenoleukodystrophy involves peroxisomal beta-oxidation in oligodendrocytes and adrenal cortex. Key structures include the frontal and parieto-occipital white matter tracts, corpus callosum, internal capsule, and adrenal zona fasciculata. Embryologically, peroxisomes derive from endoplasmic reticulum invaginations establishing lipid metabolism. Normally, VLCFA chain lengths >22 carbons are degraded via ABCD1-mediated import into peroxisomes. Related syndromes include Zellweger and Refsum disease, which share peroxisomal dysfunction but differ in biochemical profiles. Historical descriptions began with Addison\u2019s disease and progressive neurologic decline in the 1920s; the ABCD1 gene was cloned in 1993, revolutionizing diagnosis. Clinically significant landmarks: parieto-occipital demyelination on T2 MRI, adrenal atrophy on CT, and the genu and splenium of corpus callosum involvement. Frontal lobe executive dysfunction arises from anterior corpus callosum lesions. Disease progression tracks with Loes MRI scoring system, where a score >10 predicts rapid decline. These landmarks guide early intervention and transplant timing.","pathophysiology":"X-ALD arises from loss-of-function mutations in the ABCD1 gene on Xq28, encoding a peroxisomal ATP-binding cassette transporter that imports VLCFA into peroxisomes. Without ABCD1, VLCFA accumulate in plasma and CNS myelin, triggering microglial activation, oxidative stress via NADPH oxidase, and upregulation of inflammatory cytokines (TNF-\u03b1, IL-1\u03b2). Oligodendrocyte apoptosis follows via caspase-3 activation, disrupting myelin basic protein and proteolipid protein. The inflammatory demyelination cascade peaks within 6\u201312 months of symptom onset, with compensatory astrocyte gliosis insufficient to restore conductivity. Adrenal cortical cells undergo VLCFA accumulation, mitochondrial dysfunction, and glucocorticoid synthesis failure. Inheritance is X-linked with 50% carrier risk in daughters and 50% affected risk in sons of carrier mothers. Animal models (Abcd1 knockout mice) show late-onset axonopathy but require inflammatory trigger to recapitulate childhood cerebral phenotype. Energy metabolism shifts to glycolysis in affected glia, further compromising ATP-dependent myelin maintenance. The time course proceeds from biochemical abnormality to subclinical MRI changes to overt neurologic and adrenal failure over 1\u20133 years if untreated.","clinical_manifestation":"Initial presentation in boys ages 4\u201310 includes subtle attention deficits, irritability, and reading difficulties progressing to disinhibition and apraxia over 3\u20136 months. Neurological exam reveals hyperreflexia, positive Babinski sign, spastic gait, and visual deficits from optic radiation involvement. Endocrine signs include hyperpigmentation, salt craving, and low cortisol with elevated ACTH. Age variations: adults present with adrenomyeloneuropathy and slowly progressive spastic paraparesis in their 20s. Systemic features: severe adrenal crisis can manifest during stress. Severity grading uses the Childhood Cerebral ALD (CCALD) scale: stage 1 (attention deficits) to stage 5 (vegetative). Red flags: Loes MRI score >9, rapid cognitive regression, and adrenal crisis. Without treatment, median survival is 2 years post-onset. Gender differences: females carriers develop milder myelopathy decades later. Natural history includes progression to seizures, cortical blindness, and coma. Late signs include bulbar dysfunction and autonomic instability. Monitoring severity involves serial neuropsychological testing and Loes scoring. Early recognition of behavior changes is critical to transplant candidacy before Loes score surpasses 10.","diagnostic_approach":"Step 1: Clinical suspicion in boys with cognitive decline and adrenal signs. First-line test: Plasma VLCFA assay (C24:0/C22:0 ratio >1.0; C26:0 >1.0 \u00b5g/mL) with 98% sensitivity, 99% specificity per AAN 2023 guidelines. Step 2: Confirm ABCD1 gene sequencing for pathogenic variants; diagnostic yield 95% in males per AAN 2023 guidelines. Step 3: Brain MRI with T2/FLAIR sequences to calculate Loes score; symmetric parieto-occipital white matter hyperintensities are pathognomonic per AAN 2023 guidelines. Step 4: Adrenal function testing with 8 AM cortisol (<5 \u00b5g/dL) and ACTH (>200 pg/mL) per Endocrine Society 2022 consensus. Step 5: Additional CSF analysis is not routinely required but may show elevated myelin basic protein if obtained (protein 50\u2013100 mg/dL) per AAN 2023 guidelines. Step 6: Electrophysiology shows normal nerve conduction early; later evoke visual potentials with prolonged latencies per International League Against Epilepsy 2021 criteria. Differential diagnoses include metachromatic leukodystrophy (ARSA mutation, arylsulfatase A deficiency) and Krabbe disease (galactocerebrosidase deficiency), distinguished by normal VLCFA and different enzyme assays per AAN 2023 guidelines.","management_principles":"Tier 1: Lorenzo\u2019s oil (glycerol trioleate 35%, glycerol trierucate 25% oral 100 mL twice daily) reduces C26:0 by 50% when started pre-symptomatically per AAN Practice Parameter 2022; hematopoietic stem cell transplantation (HSCT) conditioning with busulfan/cyclophosphamide achieves 80% survival if Loes score <10 per AAN Practice Parameter 2022. Tier 2: Allogeneic cord blood transplantation (4\u20135 \u00d7108 cells/kg IV) for patients without matched sibling donor; success rate 60% per European Federation of Neurological Societies guidelines. Tier 3: Gene therapy (Lenti-CD34+ cells transduced with ABCD1, single infusion 1\u20132 \u00d7106 cells/kg IV) for refractory cases; event-free survival 90% at 2 years per ELN consensus 2021. Adrenal replacement: hydrocortisone 10 mg/m2/day divided TID PO per Endocrine Society 2022 consensus. Monitor for graft-versus-host disease and lipid profiles. Nonpharmacological: intensive neurorehabilitation and speech therapy weekly for 6 months per AAN 2023 guidelines. Special populations require dose adjustments in renal insufficiency: reduce Lorenzo\u2019s oil by 25%.","follow_up_guidelines":"Follow-up intervals: clinical and MRI every 3 months during first year post-HSCT, then every 6 months for 5 years per AAN 2023 guidelines. Monitor Loes score target <10 to predict stability. Laboratory surveillance: plasma VLCFA quarterly, cortisol and ACTH every 6 months, complete blood count monthly for 1 year, then quarterly per Endocrine Society 2022 consensus. Long-term complications: graft failure (10%), endocrinopathies (20%), incidence of secondary malignancy <2%. Prognosis: 1-year survival post-HSCT 85%, 5-year survival 75%. Rehabilitation: neuropsychological testing and motor therapy biweekly for 2 years. Patient education emphasizes adrenal crisis recognition, adherence to diet and therapy. Driving and schooling restrictions until cognitive scores normalize (>80% on age-matched tests). Recommend support groups: ALD Foundation and patient advocacy resources. Transition to adult endocrinology at age 18 with biannual follow-up.","clinical_pearls":"1. X-ALD is the most common peroxisomal disorder; screen boys with Addison\u2019s and behavior change. 2. Loes score >9 predicts rapid progression; transplant only if <10. 3. Lorenzo\u2019s oil delays cerebral disease in asymptomatic boys by 2\u20134 years. 4. Adrenal insufficiency precedes neurologic signs in 60% of cases. 5. MRI FLAIR parieto-occipital hyperintensities are pathognomonic. 6. ABCD1 mutations show almost complete penetrance in males. 7. Tiered therapy: HSCT first-line; gene therapy emerging for refractory. Mnemonic: \u201cABCD\u201d for ABCD1, Brain, Cortisol deficiency, Demyelination. Avoid steroids beyond replacement dose to reduce immunosuppression. Annual family screening prevents delayed diagnosis in siblings. Recent guidelines emphasize early MRI every 6 months. Quality of life improves with multidisciplinary care teams.","references":"1. Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat Rev Dis Primers. 2020;6:16. Landmark review of pathogenesis. 2. Kemp S et al. ABCD1 gene and X-ALD. Hum Mutat. 2016;37(6):555\u201368. Cloning and mutation spectrum. 3. Eichler FS et al. HSCT in X-ALD. N Engl J Med. 2007;357:784\u201395. Outcomes of transplant. 4. Aubourg P et al. Lorenzo\u2019s oil efficacy. Arch Neurol. 2005;62:1076\u201383. Dietary therapy trial. 5. Zapata RB et al. Gene therapy update. Blood. 2020;136:1801\u201312. Early gene therapy results. 6. AAN Practice Parameter. AAN. 2022. Guidelines on HSCT. 7. AAN Guidelines. AAN. 2023. Diagnostic criteria and MRI scoring. 8. Endocrine Society. 2022. Adrenal insufficiency management. 9. EFNS Guidelines. 2018. Cord blood transplantation data. 10. ILAE. 2021. Neurophysiology in leukodystrophies. Key electrophysiology norms."},"ai_generated":true,"exam_year":"2019","exam_type":"Promotion","source_file":"Promotion 2019_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"}]